About
Science & Epigenetics
Programs
Newsroom
Contact
Connect
Email
info@zenithepigenetics.com
Call
1 (587) 390-7865
Share
FAQ
Newsroom
News Releases
Presentations & Events
SEDAR Filings
News Releases
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment
November 15, 2021
Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study
September 21, 2021
Zenith Epigenetics Announces a Publication in the Journal of Cancer Gene Therapy with Compelling Data for the Treatment of ER-Positive Breast Cancer Patients
August 17, 2021
Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate Cancer
June 24, 2021
Zenith Epigenetics Announces Clinical Collaboration with Astellas
April 22, 2021
Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
March 15, 2021
© 2024 zenithepigenetics |
Legal
|
Privacy